Details for Patent: 8,551,957
✉ Email this page to a colleague
Which drugs does patent 8,551,957 protect, and when does it expire?
Patent 8,551,957 protects TRIJARDY XR, GLYXAMBI, and JARDIANCE, and is included in three NDAs.
Protection for TRIJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has fifty-three patent family members in thirty-eight countries.
Summary for Patent: 8,551,957
| Title: | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate |
| Abstract: | The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions. |
| Inventor(s): | Dugi; Klaus (Dresden, DE), Mark; Michael (Biberach, DE), Thomas; Leo (Biberach, DE), Himmelsbach; Frank (Mittelbiberach, DE) |
| Assignee: | Boehringer Ingelheim International GmbH (Ingelheim Am Rhein, DE) |
| Application Number: | 12/673,327 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,551,957 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Use; Delivery; |
Drugs Protected by US Patent 8,551,957
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-001 | Jan 27, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-002 | Jan 27, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-003 | Jan 27, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Boehringer Ingelheim | TRIJARDY XR | empagliflozin; linagliptin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 212614-004 | Jan 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,551,957
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| 07114459 | Aug 16, 2007 | |
| PCT Information | |||
| PCT Filed | August 15, 2008 | PCT Application Number: | PCT/EP2008/060736 |
| PCT Publication Date: | February 19, 2009 | PCT Publication Number: | WO2009/022007 |
International Family Members for US Patent 8,551,957
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 067970 | ⤷ Try a Trial | |||
| Argentina | 087657 | ⤷ Try a Trial | |||
| Australia | 2008288407 | ⤷ Try a Trial | |||
| Brazil | PI0815331 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
